29 Ekim 2020 Perşembe

Gilead’s Covid-19 Drug is Mediocre. It Will Be a Blockbuster Anyway.


By BY KATIE THOMAS from NYT Health Gilead Sciences said Wednesday that remdesivir, which has been authorized for emergency use since the spring, brought in $873 million in revenues so far this year. https://ift.tt/34BnUum

Hiç yorum yok:

Yorum Gönder

Routine Childhood Vaccinations in the U.S. Slipped During the Pandemic

By BY BENJAMIN MUELLER AND JAN HOFFMAN from NYT Health Nationwide, the number of kindergartners with the required shots fell below the targ...